Merck
  • Home
  • Search Results
  • [Glucocorticoid treatment for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation].

[Glucocorticoid treatment for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University (2010-02-18)
Jian-hua Lin, Zhong-lin Cui, Jie Zhou
ABSTRACT

To study the therapeutic effect of glucocorticoid on early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation. Thirteen liver transplantation recipients with serum total bilirubin above 171 micromol/L at two weeks to one month postoperatively were enrolled in this study. After exclusion of liver blood supply anomalies, bile duct complications, and acute rejection and establishment of a pathological diagnosis of cholangiole cholestasis by hepatic biopsy, hydrocortisone sodium succinate was infused. The liver functions of the patients were tested at 1 day before and 1 day and 1 week after the treatment. Hepatic biopsy was performed before and 1 week after the treatment to observe histopathological changes. The serum levels of total bilirubin decreased significantly after the treatment with glucocorticoid. Pathology of the hepatic biopsy demonstrated the resolution of cholangiole cholestasis 1 week after the treatment. Glucocorticoid treatment is effective for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrocortisone 21-hemisuccinate sodium salt, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydrocortisone 21-hemisuccinate sodium salt, ≥90% (HPLC)
Supelco
Hydrocortisone 21-hemisuccinate, analytical standard